| abstract |
The present invention includes Fc.epsilon. fragments conjugated with FC.gamma. fragments, for example, Fc.epsilon.1-Hinge-FcE2-FcE3-FcE4-FCy; Hinge-FcE2-FcE3-FcE4- Fcy; FC.epsilon.2-Fc.epsilon.3-Fc.epsilon.4-FC.gamma. ; FC.epsilon.2-Fc.epsilon.3- Fc.gamma.; FC.epsilon.3-Fc.gamma.; and FC.epsilon.3-Fc.epsilon.4-FC.gamma. , or any derivative or peptide, which has equivalent immunological function. The Fc.gamma. fragment may be a fragment of any of the IgG subclasses (lgG1 I IgG2, IgG3, or IgG4), preferably IgG1 or IgG3, wherein the fragment binds FcyRIIB. The present invention also includes compositions suitable for administering to a patient suffering from an allergic disease comprising the fusion protein construct in a pharmaceutical composition including, for example, an excipient, diluant, or carrier. This treatment may be combined with anti-IgE therapy or allergen immunotherapy. |